Last reviewed · How we verify
NCT05163652
Clinical Study of the Third Dose Immunization Schedule of COVID-19 Inactivated Vaccine, (Vero Cells) Based on Different COVID-19 Inactivated Vaccine in Adults Aged 18 Years and Above
Phase 3 trial testing SARS-CoV-2 Vaccine, Inactivated (Vero Cell) in SARS-CoV-2 Infection in 432 participants. Status unknown.
30 August 2022
Quick facts
| Lead sponsor | Chinese Academy of Medical Sciences |
|---|---|
| Phase | Phase 3 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | single group |
| Masking | none |
| Primary purpose | prevention |
| Enrollment | 432 |
| Start date | 18 December 2021 |
| Primary completion | 30 August 2022 |
| Estimated completion | 30 October 2022 |
| Sites | 1 location across China |
Drugs / interventions tested
- SARS-CoV-2 Vaccine, Inactivated (Vero Cell) — full drug profile →
Conditions studied
- SARS-CoV-2 Infection — all drugs for SARS-CoV-2 Infection →
Sponsor
Chinese Academy of Medical Sciences — full company profile →
Who can join
18 and older, any sex, with SARS-CoV-2 Infection. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To evaluate the immunogenicity and safety of the third dose SARS-CoV-2 Vaccine, Inactivated (Vero Cell) in adults aged 18 years and above, who inoculated the third dose after 3, 4, 5, or 6 months since finished two doses schedule of CoronaVac or BBIBP-CorV.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Understanding the challenges to COVID-19 vaccines and treatment options, herd immunity and probability of reinfection.
Al-Hatamleh MAI, Abusalah MA, Hatmal MM, Alshaer W, et al · · 2023 · cited 7× · PMID 36570799 · DOI 10.1016/j.jtumed.2022.11.007
Verify or expand the search:
- PubMed search for NCT05163652
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of SARS-CoV-2 Vaccine, Inactivated (Vero Cell)
Trials testing the same drug.
- NCT05216484 — Clinical Study of the Third Dose Immunization Schedule of COVID-19 Inactivated Vaccine, (Vero Cells) in Adults Aged 18 Y · Phase 3 · unknown
- NCT05164731 — Clinical Study of the Third Dose Immunization Schedule of COVID-19 Inactivated Vaccine, (Vero Cells) in Adults Aged 18 Y · Phase 3 · unknown
Other recruiting trials for SARS-CoV-2 Infection
Currently open trials in the same condition.
- NCT07079670 — Safety and Immunogenicity of NVX-CoV2705 · Phase 3 · active not recruiting
- NCT05697068 — Intervention to Prevent Household and Community Spread of COVID-19 Among Latinos · NA · active not recruiting
- NCT05172011 — Understanding the Long-term Impact of COVID on Children and Families · active not recruiting
- NCT05141058 — T Cell Therapy Opposing Novel COVID-19 Infection in Immunocompromised Patients · Phase 1 · recruiting
- NCT05046470 — SARS-CoV-2 Transmission in Belgian Primary Schools of the Federation Wallonia - Brussels: An Epidemiological Pilot Study · active not recruiting
Other Chinese Academy of Medical Sciences trials
Trials by the same sponsor.
- NCT05522894 — AK104 Alone or in Combination With Chemotherapy in the First-line Treatment of ESCC · Phase 2 · unknown
- NCT05499715 — A Phase I Clinical Study to Evaluate the Safety, the Tolerability, the Pharmacokinetic Characteristics and the Efficacy · Phase 1 · unknown
- NCT05484024 — Short-course Radiotherapy Followed by Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal Cancer · Phase 2, PHASE3 · not yet recruiting
- NCT05543070 — Low-dose Radiotherapy in iNHL · Phase 2 · unknown
- NCT05460403 — Adjuvant Radiotherapy for Patients With Esophageal Squamous Cell Carcinoma After R0 Resection · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05163652 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Chinese Academy of Medical Sciences
- Last refreshed: 2 March 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05163652.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing